Biochemical markers of joint tissue turnover

Assay and Drug Development Technologies

Volumn 8, Issue 1, 2010, Pages 118-124

  Bay Jensen, Anne Christine ^a   Sondergaard, Bodil Cecilie ^a   Christiansen, Claus ^a   Karsdal, Morten A ^a   Madsen, Suzi Høgh ^a   Qvist, Per ^a,b  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; GLYCOPROTEIN GP 39; HYALURONIC ACID; OSTEOCALCIN; PROCOLLAGEN C PROTEINASE;

ARTICULAR CARTILAGE; BONE TISSUE; BONE TURNOVER; DISEASE MARKER; HUMAN; JOINT; OSSIFICATION; OSTEOARTHRITIS; REVIEW; SYNOVIUM;

BIOLOGICAL MARKERS; BONE REMODELING; CARTILAGE, ARTICULAR; DRUG DISCOVERY; HUMANS; JOINTS; OSTEOARTHRITIS; SYNOVIAL MEMBRANE;

EID: 77649140788     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2009.0199     Document Type: Review

References (64)

1. Krasnokutsky S, Samuels J, Abramson SB: Osteoarthritis in 2007. Bull NYU Hosp Jt Dis 2007;65(3):222-228.
2. Rousseau JC, Delmas PD: Biological markers in osteoarthritis. Nat Clin Pract Rheumatol 2007;3(6):346-356.
3. Sumer EU, Schaller S, Sondergaard BC, Tanko LB, Qvist P: Application of biomarkers in the clinical development of new drugs for chondroprotection in destructive joint diseases: a review. Biomarkers 2006;11(6):485-506.
4. Abramson SB, Attur M, Yazici Y: Prospects for disease modification in osteoarthritis. Nat Clin Pract Rheumatol 2006;2:304-312.
5. Garnero P: Use of biochemical markers to study and follow patients with osteoarthritis. Curr Rheumatol Rep 2006;8(1):37-44
6. Kraus VB: Do biochemical markers have a role in osteoarthritis diagnosis and treatment? Best Pract Res Clin Rheumatol 2006;20(1):69-80.
7. Schaller S, Henriksen K, Hoegh-Andersen P, Sondergaard BC, Sumer EU, Tanko LB, et al.: In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol 2005;3:553-580.
8. Samuels J, Krasnokutsky S, Abramson SB: Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis 2008;66(3):244-250.
9. Fosang AJ, Stanton H, Little CB, Atley LM: Neoepitopes as biomarkers of cartilage catabolism. Inflamm Res 2003;52(7):277-282.
10. Zhen EY, Brittain IJ, Laska DA, Mitchell PG, Sumer EU, Karsdal MA, et al.: Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum 2008;58(8):2420-2431.
11. Behrens F, Kraft EL, Oegema TR: Biochemical changes in articular cartilage after joint immobilization by casting or external fixation. J Orthop Res 1989;7:335-343.
12. Bondeson J, Wainwright S, Hughes C, Caterson B: The regulation of the ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review. Clin Exp Rheumatol 2008;26(1):139-145.
13. Nagase H, Kashiwagi M: Aggrecanases and cartilage matrix degradation Arthritis Res Ther 2003;5(2):94-103.
14. Gendron C, Kashiwagi M, Lim NH, Enghild JJ, Thogersen IB, Hughes C, et al.: Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4. J Biol Chem 2007;282(25):18294-18306.
15. Garnero P, Delmas PD: Biomarkers in osteoarthritis. Curr Opin Rheumatol 2003;15(5):641-646.
16. Mazieres B, Garnero P, Gueguen A, Abbal M, Berdah L, Lequesne M, et al.: Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort. Ann Rheum Dis 2006;65(3):354-359.
17. Reijman M, Hazes JM, Bierma-Zeinstra SM, Koes BW, Christgau S, Christiansen C, et al.: A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 2004;50(8):2471-2478.
18. Dam EB, Byrjalsen I, Karsdal MA, Qvist P, Christiansen C: Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage 2009;17(3):384-389.
19. Hunter DJ, Li J, LaValley M, Bauer DC, Nevitt M, DeGroot J, et al.: Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study. Arthritis Res Ther 2007;9(5):R108.
20. Downs JT, Lane CL, Nestor NB, McLellan TJ, Kelly MA, Karam GA, et al.: Analysis of collagenase-cleavage of type II collagen using a neoepitope ELISA. J Immunol Methods 2001;247(1-2):25-34.
21. Manicourt DH, Azria M, Mindeholm L, Thonar EJ, Devogelaer JP: Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 2006;54(10):3205-3211.
22. Bingham CO, III, Buckland-Wright JC, Garnero P, Cohen SB, Dougados M, Adami S, et al.: Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006;54(11):3494-3507.
23. Garnero P, Aronstein WS, Cohen SB, Conaghan PG, Cline GA, Christiansen C, et al.: Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthritis Cartilage 2008;16(6):660-666.
24. Charni N, Juillet F, Garnero P: Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2005;52(4):1081-1090.
25. Charni N, Desmarais S, Bay-Jensen A, Delaisse JM, Percival MD, Garnero P: The type II collagen fragments Helix-II and CTX-II reveal distinct enzymatic pathways of cartilage collagen degradation. Osteoarthritis Cartilage 2008;16(10):1183-1191.
26. Eyre DR, Weis MA: The Helix-II epitope: a cautionary tale from a cartilage biomarker based on an invalid collagen sequence. Osteoarthritis Cartilage 2009;17(4):423-426.
27. Olsen AK, Sondergaard BC, Byrjalsen I, Tanko LB, Christiansen C, Muller A, et al.: Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen. Osteoarthritis Cartilage 2007;15: 335-342.
28. Nemirovskiy OV, Sunyer T, Aggarwal P, Abrams M, Hellio Le Graverand MP, Mathews WR: Discovery and development of the N-terminal procollagen type II (NPII) biomarker: a tool for measuring collagen type II synthesis. Osteoarthritis Cartilage 2008;16(12):1494-1500.
29. Rousseau J-C, Zhu Y, Miossec P, Vignon E, Sandell LJ, Garnero P, et al.: Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2004;12(6):440-447.
30. Sharif M, Kirwan J, Charni N, Sandell LJ, Whittles C, Garnero P: A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis-association with disease progression. Rheumatology (Oxford) 2007;46(6):938-943.
31. Struglics A, Larsson S, Pratta MA, Kumar S, Lark MW, Lohmander LS: Human osteoarthritis synovial fluid and joint cartilage contain both aggrecanaseand matrix metalloproteinase-generated aggrecan fragments. Osteoarthritis Cartilage 2006;14(2):101-113.
32. Pratta MA, Su JL, Leesnitzer MA, Struglics A, Larsson S, Lohmander LS, et al.: Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments. Osteoarthritis Cartilage 2006;14(7):702-713.
33. Sumer EU, Sondergaard BC, Rousseau JC, Delmas PD, Fosang AJ, Karsdal MA, et al.: MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays. Osteoarthritis Cartilage 2007;15(2):212-221.
34. Rousseau JC, Sumer EU, Hein G, Sondergaard BC, Madsen S, Pedersen C, et al.: Patients with rheumatoid arthritis have an altered circulatory aggrecan profile. BMC Musculoskelet Disord 2008;9(1):74.
35. Goldring SR: Role of bone in osteoarthritis pathogenesis. Med Clin North Am 2009;93(1):25-35, xv.
36. Karsdal MA, Leeming DJ, Dam EB, Henriksen K, Alexandersen P, Pastoureau P, et al.: Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage 2008;16(6):638-646.
37. Felson DT, Neogi T: Osteoarthritis: is it a disease of cartilage or of bone? Arthritis Rheum 2004;50(2):341-344.
38. Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E: Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis 2001;60(6):619-626.
39. Bruyere O, Collette J, Delmas P, Rouillon A, Roux C, Seidel L, et al.: Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. Maturitas 2003;44(4):259-265.
40. Gineyts E, Garnero P, Delmas PD: Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation. Rheumatology (Oxford) 2001;40(3):315-323.
41. Garnero P, Rousseau J-C, Delmas PD: Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum 2000;43:953-968.
42. Marotte H, Gineyts E, Miossec P, Delmas PD: Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis. Ann Rheum Dis 2009;68:1197-1200.
43. Glant TT, Mikecz K, Roughley PJ, Buzas E, Poole AR: Age-related changes in protein-related epitopes of human articular-cartilage proteoglycans. Biochem J 1986;236:71-75. (Pubitemid 16095514)
44. Rizkalla G, Reiner A, Bogoch E, Poole AR: Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest 1992;90:2268-2277.
45. Mansson B, Carey D, Alini M, Ionescu M, Rosenberg LC, Poole AR et al.: Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest 1995;95:1071-1077.
46. Emery P, Gabay C, Kraan M, Gomez-Reino J: Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int 2007;27:793-806.
47. Saxne T, Heinegard D: Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol 1992;31:583-591.
48. Melkko J, Niemi S, Risteli L, Risteli J: Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990;36:1328-1332.
49. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, et al.: Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 1996;42:947-954.
50. Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, et al.: Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 1998;44:2281-2289.
51. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR: A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-1258.
52. Elomaa I, Virkkunen P, Risteli L, Risteli J: Serum concentration of the crosslinked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992;66:337-341.
53. Olsen AK, Sondergaard BC, Byrjalsen I, Tanko LB, Christiansen C, Muller A, et al.: Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen. Osteoarthritis Cartilage 2007;15: 335-342.
54. Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, et al.: Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002;46:2613-2624.
55. Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, et al.: Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 2001;29:209-215.
56. Lohmander LS, Atley LM, Pietka TA, Eyre DR: The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum 2003;48:3130-3139.
57. Hellio Le Graverand MP, Brandt KD, Mazzuca SA, Katz BP, Buck R, Lane KA, et al.: Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis. Osteoarthritis Cartilage 2006;14:1189-1195.
58. Poole AR, Ionescu M, Fitzcharles MA, Billinghurst RC: The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Methods 2004;294:145-153.
59. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al.: Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-1545.
60. Risteli J, Niemi S, Trivedi P, Maentausta O, Mowat AP, Risteli L: Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem 1988;34:715-718.
61. Johansen JS, Jensen HS, Price PA: A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993;32:949-955.
62. Krzeski P, Buckland-Wright C, Balint G, Cline GA, Stoner K, Lyon R, et al.: Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther 2007;9(5):R109.
63. Garnero P, Charni N, Juillet F, Conrozier T, Vignon E: Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis. Ann Rheum Dis 2006;65(12):1639-1644.
64. Bauer DC, Hunter DJ, Abramson SB, Attur M, Corr M, Felson D, et al.: Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 2006;14(8):723-727.